Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Batten Disease – Pipeline Review, H1 2017

Monday, March 20, 2017 3:00
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Ethocle Reports has published its latest Market Research Report on Batten Disease – Pipeline Review, H1 2017. Batten Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Browse market data tables and figure.

 

                                                                                                                Published On: 15-Mar-2017 | Pages: 73  

Summary

Pharmaceutical and Healthcare disease pipeline guide Batten Disease – Pipeline Review, H1 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape.

Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems.

Capture.PNG     d.PNG     dd.PNG

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Batten Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Batten Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Batten Disease (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Batten Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Batten Disease (Central Nervous System).

Table of Contents

Introduction

Global Markets Direct Report Coverage

Batten Disease – Overview

Batten Disease – Therapeutics Development

Pipeline Overview

Products under Development by Companies

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Batten Disease – Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

BioMarin Pharmaceutical Inc

CereSpir Inc

Evotec AG

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.